Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Biopharma deal-making in 2017

Nature Reviews Drug Discovery volume 17, pages 91–92 (2018)Cite this article

Subjects

Access through your institution
Buy or subscribe

The total value of mergers and acquisitions (M&As) in 2017 reached US$136 billion, according to Informa's Medtrack and Strategic Transactions, representing a 30% increase over 2016's $105 billion aggregate (Nat. Rev. Drug Discov. 16, 161–162; 2017). The industries included in the value broadly cover biopharma, as well as consumer and over-the-counter (OTC) drugs, drug delivery technologies, contract research and manufacturing and clinical trial services, but exclude devices, diagnostics, research tools, insurance (for example, the $77 billion merger between CVS and Aetna is excluded) and animal health.

At $30 billion, Johnson & Johnson's acquisition of Actelion Pharmaceuticals was the largest M&A deal of 2017. It boosted the large pharma company's assets in cardiology with Actelion's pulmonary arterial hypertension franchise, which includes bosentan (Tracleer) and the anticipated blockbuster follow-on product macitentan (Opsumit). Under the transaction, Actelion spun off drug discovery operations and some early-stage candidates into a separate company called Idorsia, in which Johnson & Johnson took a 16% stake, as well as an option on the phase II drug ACT132577 for resistant hypertension that it exercised in late 2017. Another notable biopharma acquisition in a breakthrough year for cell and gene therapies was Gilead Sciences' $11.9 billion takeover of Kite Pharma, which gained FDA approval last year for one of the first two chimeric antigen receptor (CAR) T cell anticancer therapies, axicabtagene ciloleucel (Yescarta).

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biopharma deal-making in 2017.

Author information

Authors and Affiliations

  1. Informa, 52 Vanderbilt Avenue, New York, 10017, New York, USA

    Amanda Micklus & Steven Muntner

Authors
  1. Amanda Micklus
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Steven Muntner
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Amanda Micklus.

Supplementary information

Supplementary information S1 (figure)

Distribution of the 18 M&A deals in 2017 worth >US$1 billion by target focus. (PDF 213 kb)

Supplementary information S2 (table)

Top 10 partnership deals of 2017 by total announced deal value (PDF 136 kb)

Supplementary information S3 (figure)

Partnership deal activity in 2017 by phase of development. (PDF 115 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Micklus, A., Muntner, S. Biopharma deal-making in 2017. Nat Rev Drug Discov 17, 91–92 (2018). https://doi.org/10.1038/nrd.2018.1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research